| Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be presented at the European Hematology Association Annual Congress, taking place June 12 - 15, 2025, in Milan, Italy. Additional data from this trial will be presented at the International Conference on Malignant Lymphoma, taking place June 17 - 21, 2025, in Lugano, Switzerland. The Phase 1 study is designed to evaluate the safet. |
businesswire.com |
2025-05-14 13:30:00 |
Czytaj oryginał (ang.) |
| Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates |
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.76 per share a year ago. |
zacks.com |
2025-05-07 23:40:30 |
Czytaj oryginał (ang.) |
| Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript |
Schrödinger, Inc. (NASDAQ:SDGR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Michael Yee - Jefferies Brendan Smith - TD Cowen Mani Foroohar - Leerink Partners Evan Seigerman - BMO Capital Markets Michael Ryskin - Bank of America Scott Schoenhaus - KeyBanc Vikram Purohit - Morgan Stanley Operator Thank you for standing by. Welcome to Schrödinger's conference call to review First Quarter 2025 Financial Results. |
seekingalpha.com |
2025-05-07 21:59:25 |
Czytaj oryginał (ang.) |
| Schrödinger Reports Strong First Quarter 2025 Financial Results |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced financial results for the quarter ended March 31, 2025. |
businesswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Schrödinger to Present at BofA Securities 2025 Healthcare Conference |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference. The live presentation will take place on Wednesday, May 14, 2025 at 4:40 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computatio. |
businesswire.com |
2025-05-05 12:30:00 |
Czytaj oryginał (ang.) |
| Schrödinger Presents New Preclinical Data at AACR Annual Meeting |
CHICAGO--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) presented preclinical data on SGR-3515, its investigational Wee1/Myt1 co-inhibitor today at the American Association for Cancer Research (AACR) Annual Meeting 2025. The data demonstrated that SGR-3515 has improved anti-tumor activity in preclinical models compared to known Wee1 and Myt1 monotherapy inhibitors. The poster also described how the dosing schedule of SGR-3515 can be optimized to preserve efficacy and minimize target-related. |
businesswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| Schrödinger to Announce First Quarter 2025 Financial Results on May 7 |
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close. |
businesswire.com |
2025-04-23 12:30:00 |
Czytaj oryginał (ang.) |
| 3 Momentum Stocks That Could Soar Post-Market Volatility |
While the impact of unanticipated tariff policy changes in early April was market-wide, the recovery has been less even. Despite a major rebound following the sell-off, some firms have been sluggish to reclaim lost ground. |
marketbeat.com |
2025-04-21 12:02:54 |
Czytaj oryginał (ang.) |
| Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on April 16, 2025, the company granted (i) a non-statutory stock option to purchase 3,300 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 12,866 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of. |
businesswire.com |
2025-04-18 12:30:00 |
Czytaj oryginał (ang.) |
| Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) strongly supports the U.S. Food and Drug Administration's (FDA) plan to reduce, refine or potentially replace current animal testing requirements with new approaches designed to improve drug safety and accelerate the evaluation process, while reducing animal experimentation. The FDA's roadmap encourages a number of computational approaches to predict drug properties. Schrödinger's widely used computational platform enables highly accur. |
businesswire.com |
2025-04-14 12:00:00 |
Czytaj oryginał (ang.) |
| Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last? |
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2025-04-14 09:20:35 |
Czytaj oryginał (ang.) |
| Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade) |
Schrödinger's stock surged after the FDA's initiative to phase out animal testing, benefiting its computational drug discovery platform. The company has strong collaborations with big pharma and a promising internal pipeline, despite past financial struggles and intense competition. Schrödinger's predictive toxicology initiative aligns with regulatory trends, enhancing drug development efficiency and safety. |
seekingalpha.com |
2025-04-12 14:26:47 |
Czytaj oryginał (ang.) |
| Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 15, 2025, the company granted (i) a non-statutory stock option to purchase 1,575 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 6,943 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of. |
businesswire.com |
2025-03-18 10:30:00 |
Czytaj oryginał (ang.) |
| Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. |
businesswire.com |
2025-03-10 10:30:00 |
Czytaj oryginał (ang.) |
| Schrödinger: Still Waiting On A Catalyst |
Schrödinger's Q4 2024 results and 2025 guidance were solid, yet the company's share price remains low due to ongoing losses. Cash burn is likely to moderate going forward, as investments in the company's internal pipeline have now stabilized. Regardless, cash burn concerns are misplaced, as Schrödinger has demonstrated that it can manage its liquidity position through things like partnerships and licensing. |
seekingalpha.com |
2025-03-02 03:24:27 |
Czytaj oryginał (ang.) |
| Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript |
Schrödinger, Inc. (NASDAQ:SDGR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Affairs Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President, R&D & Therapeutics Conference Call Participants Kyle Yang - Jefferies CJ Yeh - Leerink Partners Brendan Smith - TD Cowen Michael Ryskin - Bank of America Vikram Purohit - Morgan Stanley Malcolm Hoffman - BMO Capital Markets Matt Hewitt - Craig-Hallum Capital Group Chris Shibutani - Goldman Sachs Operator Thank you for standing by. Welcome to Schrödinger's conference call to review Fourth Quarter and Full Year 2024 Financial Results. |
seekingalpha.com |
2025-02-26 21:27:05 |
Czytaj oryginał (ang.) |
| Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates |
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.32 per share a year ago. |
zacks.com |
2025-02-26 21:00:28 |
Czytaj oryginał (ang.) |
| Schrödinger to Participate in Upcoming Investor Conferences |
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 45th Annual Health Care Conference: Fireside chat on Tuesday, March 4, 2025 at 10:30 a.m. E.T. Leerink Partners Global Biopharma Conference 2025: Fireside chat on Monday, March 10, 2025 at 3:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 18, 2025 at 9:00 a.m. E.T. The live discussions can be accessed in the “Investors” sectio. |
businesswire.com |
2025-02-24 10:30:00 |
Czytaj oryginał (ang.) |
| Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26 |
NEW YORK--(BUSINESS WIRE)--Schrödinger will report its fourth quarter and full-year 2024 financial results on Wednesday, February 26, 2025, after the financial markets close. |
businesswire.com |
2025-02-12 10:30:00 |
Czytaj oryginał (ang.) |
| Schrodinger (SDGR) Moves 14.1% Higher: Will This Strength Last? |
Schrodinger (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-01-23 06:45:25 |
Czytaj oryginał (ang.) |
| Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. “We are very proud of our accomplishments in 2024. We advanced the capabilities of our computational platform and leveraged the synergies in our business, which included signing a multi-target research collaboration and expanded software licensing agreement with Novartis. We are pleased another innovative pharmaceutical. |
businesswire.com |
2025-01-13 09:00:00 |
Czytaj oryginał (ang.) |
| Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 12, 2024, the company granted restricted stock units (RSUs) with respect to 8,365 shares of the company's common stock to six newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement. |
businesswire.com |
2024-12-17 10:30:00 |
Czytaj oryginał (ang.) |
| Schrödinger Broadens and Accelerates Predictive Toxicology Initiative |
NEW YORK--(BUSINESS WIRE)--Schrödinger broadens and accelerates predictive toxicology initiative. |
businesswire.com |
2024-11-18 10:30:00 |
Czytaj oryginał (ang.) |
| Schrodinger price target raised to $28 from $27 at Goldman Sachs |
Goldman Sachs raised the firm's price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company's Q3 results and announced deal with Novartis (NVS) involving both a research and expanded software utilization collaboration drove the stock higher, and while operating results from the quarter came in slightly below expectations, the management relayed confidence in the forward outlook for the balance of the year for the company's Software business, noting resiliency across large and mid-sized ACV accounts with increasing depth of utilization, the analyst tells investors in a research note. Schrodinger -0.165 (-0.74%) Novartis -1.08 (-1.03%) |
https://thefly.com |
2024-11-13 19:17:42 |
Czytaj oryginał (ang.) |
| Schrödinger (SDGR) Q3 2024 Earnings Call Transcript |
Schrödinger Inc. (NASDAQ:SDGR ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Ramy Farid - President, Chief Executive Officer Karen Akinsanya - President, R&D and Therapeutics Geoff Porges - Chief Financial Officer Jaren Madden - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Matt - Jefferies Mani Foroohar - Leerink Partners Steve - Keybanc Gaspa - Morgan Stanley Evan Seigerman - BMO Capital Markets Joe Catanzaro - Piper Sandler Toff - Craig Hallum Brendan Smith - TD Cowen Sean Kim - Bank of America John - Citi Operator Welcome to Schrödinger's conference call to review our third quarter 2024 financial results. My name is Madison and I will be your Operator for today's call. |
seekingalpha.com |
2024-11-12 12:51:41 |
Czytaj oryginał (ang.) |
| Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates |
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.86 per share a year ago. |
zacks.com |
2024-11-12 11:06:09 |
Czytaj oryginał (ang.) |
| Schrödinger Reports Third Quarter 2024 Financial Results |
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the third quarter of 2024 and provided a business update. |
businesswire.com |
2024-11-12 08:50:00 |
Czytaj oryginał (ang.) |
| Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis |
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis. |
businesswire.com |
2024-11-12 08:45:00 |
Czytaj oryginał (ang.) |
| Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium |
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1. The preclinical data also show that SGR-3515 has a favorable ph. |
businesswire.com |
2024-10-23 10:01:00 |
Czytaj oryginał (ang.) |
| Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on October 12, 2024, the company granted (i) a non-statutory stock option to purchase 5,700 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 15,890 shares of the company's common stock to seven newly hired employees. These grants were ma. |
businesswire.com |
2024-10-17 12:30:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Schrodinger, Inc. to Contact Law Firm |
NEW YORK , Sept. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Schrodinger, Inc. (NASDAQ: SDGR) breached their fiduciary duties to shareholders. |
prnewswire.com |
2024-09-19 18:18:00 |
Czytaj oryginał (ang.) |
| Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported that on September 13, 2024, the company granted restricted stock units (RSUs). |
businesswire.com |
2024-09-18 12:30:00 |
Czytaj oryginał (ang.) |
| 2 Bill Gates stocks to turn $100 into $1,000 by 2025 |
Bill Gates has been named the world's richest man a record 18 times. Although the billionaire has shifted his focus to philanthropic efforts as time has gone on, the Bill & Melinda Gates Foundation Trust still relies on stock investments to finance its worthwhile goals. |
finbold.com |
2024-09-03 11:39:35 |
Czytaj oryginał (ang.) |
| The 3 Best Med Tech Stocks to Buy Now |
According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments. |
investorplace.com |
2024-08-05 15:20:44 |
Czytaj oryginał (ang.) |
| Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript |
Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Jaren Madden - Senior Vice President, Investor Relations & Corporate Communications Ramy Farid - President & Chief Executive Officer Geoff Porges - Chief Financial Officer Karen Akinsanya - President R&D, Therapeutics Conference Call Participants Michael Yee - Jefferies Scott Schoenhaus - KeyBanc Conor McKay - BMO Capital Markets David Leibowitz - Citi Matt Hewitt - Craig-Hallam Capital Chris Shibutani - Goldman Sachs Steven Mah - TD Cowen Operator Thank you for standing by. Welcome to Schrödinger's Conference Call to review our Second Quarter 2024 Financial Results. |
seekingalpha.com |
2024-08-01 04:46:07 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Schrodinger (SDGR) Q2 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Schrodinger (SDGR) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2024-08-01 01:05:49 |
Czytaj oryginał (ang.) |
| Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates |
Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.21 per share a year ago. |
zacks.com |
2024-07-31 23:40:30 |
Czytaj oryginał (ang.) |
| 3 Small-Cap Stocks to Buy at a 52-Week Low |
Small-cap stocks have taken a beating in the last two years. After the meme stock craze of 2021 died down, investors found they could get more predictable thrills from large-cap technology stocks. |
investorplace.com |
2024-07-27 11:10:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline |
Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-07-24 15:07:14 |
Czytaj oryginał (ang.) |
| 3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts |
Inflation is trending downward and approaching the Federal Reserve's 2% target and unemployment is heading higher. The Fed is widely expected to begin cutting interest rates at its September meeting. |
investorplace.com |
2024-07-23 00:07:17 |
Czytaj oryginał (ang.) |
| Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
NEW YORK--(BUSINESS WIRE)--Schrödinger today reported that on July 12, 2024, the company granted restricted stock units (RSUs). |
businesswire.com |
2024-07-16 12:30:00 |
Czytaj oryginał (ang.) |